JPRN-jRCT2080223181已完成2 期
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- MSD K.K.
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Have a histologically-confirmed diagnosis of high-risk non-muscle-invasive (T1, High Grade Ta and/or CIS) transitional cell carcinoma of the bladder. Subjects with tumors of mixed transitional/non-transitional cell histology are allowed, but transitional cell carcinoma must be the predominant histology.
- •- Fully resected disease at study entry (residual CIS acceptable).
- •- Have been treated with adequate BCG therapy and have developed high-risk NMIBC that is unresponsive to BCG therapy.
- •- Have elected not to undergo, or are considered ineligible for radical cystectomy, as determined by the treating surgeon.
- •- Have provided tissue for biomarker analysis from the most recent cystoscopy/TURBT procedures from which tumor sample is available.
- •- Have a performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
- •- Have adequate organ function.
- •- Female participants of childbearing potential have a negative urine or serum pregnancy test and must be willing to use an adequate method of contraception.
- •- Male participants must be willing to use an adequate method of contraception.
排除标准
- •- Has muscle-invasive, locally advanced nonresectable, or metastatic urothelial carcinoma (i.e., T2, T3, T4, and / or stage IV).
- •- Has concurrent extra-vesical (i.e., urethra, ureter, or renal pelvis) non-muscle invasive transitional cell carcinoma of the urothelium.
- •- Currently participating or has participated in a study of an investigational agent and received study therapy or received investigational device within 4 weeks prior to the first dose of study treatment.
- •- Received intervening intravesical chemotherapy or immunotherapy from the time of most recent cystoscopy / Transurethral Resection of Bladder Tumor (TURBT) to starting study treatment.
- •- Received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to starting study treatment or not recovered from adverse events due to a previously administered agent.
- •- Known additional malignancy that is progressing or requires active treatment excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. A history of prostate cancer that was treated with definitive intent (surgically or through radiation therapy) is acceptable provided that the following criteria are met: Stage T2N0M0 or lower; Gleason score <=7 and prostatic-specific antigen (PSA) undetectable for at least 1 year while off androgen deprivation therapy that was either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to study allocation.
- •- Active autoimmune disease that has required systemic treatment in the past 2 years.
- •- Evidence of interstitial lung disease or active non-infectious pneumonitis.
- •- Active infection requiring systemic therapy.
- •- Pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial through 120 days after the last dose of study treatment.
- •- Prior therapy with an anti-programmed cell death 1 (PD-1), anti-PD-ligand 2 (L2) agent, or with an agent directed to another co-inhibitory T-cell receptor.
- •- Known human immunodeficiency virus (HIV).
- •- Known active Hepatitis B or C infection.
- •- Received a live virus vaccine within 30 days of planned start of study treatment.
- •- Has had an allogeneic tissue/solid organ transplant.
研究者
相似试验
招募中
2 期
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy10038364Bladder CancerNL-OMON46995Merck Sharp & Dohme (MSD)20
进行中（未招募）
1 期
Pembrolizumab (MK-3475) and Pembrolizumab in combination with other agents in High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients Unresponsive to Bacillus Calmette-Guerin (BCG) Therapyon-Muscle Invasive Bladder Cancer (NMIBC)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004026-17-FIMerck Sharp & Dohme LLC320
进行中（未招募）
1 期
Pembrolizumab (MK3457) in high risk Non-muscle Invasive Bladder CancerEUCTR2014-004026-17-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc260
招募中
1 期
Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCGon-Muscle Invasive Bladder Cancer (NMIBC)MedDRA version: 20.0Level: LLTClassification code: 10005004Term: Bladder cancer NOS Class: 10029104CTIS2022-502526-41-00Merck Sharp & Dohme LLC356
进行中（未招募）
1 期
Pembrolizumab (MK-3475) in High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients Unresponsive to Bacillus Calmette-Guerin (BCG) TherapyEUCTR2014-004026-17-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.260